About the CaPP3 Study

Professor Sir John Burn, Chief Investigator

About the CaPP3 Study - watch on YouTube

CaPP3 closed to recruitment on 31st March 2019

The Cancer Prevention Project 3 (CaPP3) focusses first on finding the right dose of aspirin for people with a mismatch repair gene defect, the underlying cause of Lynch syndrome.  Three thousand people who have Lynch syndrome are taking part in a dose non-inferiority trial. On joining the study the recruits were asked to provide a blood sample before receiving a supply of enteric coated aspirin tablets.  The recruits took three tablets each day for two years. One was a dummy tablet and at least one contained aspirin.  We kept a secret code so that no-one knew whether they were taking 100mg, 300mg or 600mg of aspirin per day.  The blood samples will help us to investigate whether some people react differently to aspirin and also whether we can predict, using blood markers, who will develop cancers in the future.  Everyone who took part in CaPP3 were invited to be part of a national registry which can provide careful follow-up to report side effects and provide detailed information about any cancers or polyps which are found on routine checkups.

The CaPP3 study is recruited through the UK Regional Genetics Centres. International centres including Spain, Finland, Israel and Australia secured funding to be involved in the study. 

Some people who started in the CAPP2 study are also involved in the CaPP3 study.  

Analysis will start after the last patient last visit which will be during the second quarter of 2024.  Results should be published 2024/2025.